{
  "id": "CD012532.PUB2",
  "draft": "What impact do immune checkpoint inhibitors have on treating glioma?\n\nKey messages\n\n- For people with glioma (an aggressive brain tumour), medicines that help the immune system fight cancer ('immune checkpoint inhibitors') probably do not help them live longer or stop the cancer from growing. We are also uncertain about their serious unwanted effects.\n- We found one small study suggesting that giving an immune checkpoint inhibitor before and after surgery might help people whose brain tumour has returned.\n- Because the evidence is limited and uncertain, we need larger and better-designed studies to find out if immune checkpoint inhibitors can help treat glioma.\n\nWhat is glioma?\n\nGlioma is a type of brain cancer. The most common and aggressive type is called glioblastoma. People diagnosed with it often live for a very short time. This cancer is hard to treat because it weakens the body's immune system, which stops it from fighting the cancer well. A type of medicine called an 'immune checkpoint inhibitor' is designed to help the immune system find and attack cancer cells.\n\nWhat did we want to find out?\n\nWe wanted to find out if using immune checkpoint inhibitors to treat adults with glioma is effective and safe. We were interested in whether these treatments helped people live longer, stopped the cancer from growing for longer, and if they caused any serious unwanted effects.\n\nHow did we conduct the review?\n\nWe searched for studies called randomised controlled trials, where people are put into different treatment groups by chance. We looked for trials that compared immune checkpoint inhibitor medicines against other treatments or a placebo (a dummy treatment) for adults with glioma. We then compared and summarised the results of the studies. We also judged how certain the evidence made us about the findings.\n\nWhat did we find?\n\nWe found 7 studies with a total of 1953 adults with glioblastoma. The number of people in each study ranged from 35 to 716. 4 studies included people whose glioblastoma had returned. 3 studies included people with newly diagnosed glioblastoma, one of which focused on older adults. The studies tested two immune checkpoint inhibitors: nivolumab and pembrolizumab. People in the studies received these medicines either alone or with other cancer treatments. Their results were compared to people who received other treatments or a placebo.\n\nWhat are the main results?\n\nFor people whose glioblastoma has returned, the medicine nivolumab alone probably makes little to no difference to how long they live or to stopping the cancer from growing for longer. This was compared to another medicine for brain tumours. Giving a different immune medicine, pembrolizumab, both before and after surgery may help people live longer, but we are very uncertain about this result. For other combinations of these treatments, it is unclear if they affect how long people live or if they cause serious unwanted effects.\n\nFor people with newly diagnosed glioblastoma, adding the immune medicine nivolumab to standard radiation therapy probably makes little to no difference to how long they live or to stopping the cancer from growing for longer. When nivolumab is added to standard radiation and chemotherapy, it also probably makes little to no difference to how long people live. However, it probably increases serious unwanted effects. It makes little to no difference to less serious unwanted effects.\n\nOverall, the evidence we reviewed suggests these specific immune-based treatments do not work well for glioblastoma. They probably do not help people live longer and may increase serious unwanted effects in some cases. For many results, the evidence is very uncertain.\n\nWhat are the limitations of the evidence?\n\nWe have little confidence in the evidence for a few reasons. In some studies, people may have known which treatment they were receiving. Knowing which treatment they received could affect the results, because what people expect from a treatment can change how they feel or the symptoms they report. Also, the studies included different types of people, and we did not find enough studies to be certain about the findings.\n\nHow up to date is this evidence?\n\nThis evidence is up to date to March 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 707,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 44,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 16.068181818181817,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 18,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 88,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 50,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 20,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 169,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 169.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 56.8649750867944,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 9.319589494663752,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.63445866015173,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 11.10913719943423,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 13.103368908319403,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 42.093641507007845,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 4.181818181818182,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 13.344080432788601,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 6.581437263726373,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 259,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 259.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 118,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 118.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 184,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 184.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 707,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 707 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 8,
        "P50_count": 0,
        "P75_count": 6,
        "P90_count": 4,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 44.44444444444444,
        "P50_percentage": 0,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 22.22222222222222,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 77.77777777777779,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The critical checks for this summary have passed, including word count and factual accuracy. However, the draft is not approved because its reliance on technical drug names and complex vocabulary makes it difficult for a lay audience to understand, despite good overall readability scores. The PLS evaluation supports this, showing the number of complex words, long words, and nouns are much higher than is typical for a Plain Language Summary. To improve the summary, please focus on the following 3 areas:\n\n1. **Avoid specific drug names.** Using technical names like 'nivolumab' and 'pembrolizumab' is confusing for readers. Refer to them generically.\n    *   **Instead of:** 'For people whose glioblastoma has returned, the medicine nivolumab alone probably makes little to no difference...'\n    *   **Consider:** 'For people whose glioblastoma has returned, using one of the immune medicines alone probably makes little to no difference...'\n\n2. **Simplify descriptions of outcomes.** Some phrases describing the results are awkward and could be clearer.\n    *   **Instead of:** '...makes little to no difference to how long they live or to stopping the cancer from growing for longer.'\n    *   **Consider:** '...makes little to no difference to how long they live or how long they live without the cancer growing.'\n\n3. **Make the 'Limitations' section more concrete.** The explanation of bias is abstract and could be easier to grasp with a more direct example.\n    *   **Instead of:** 'In some studies, people may have known which treatment they were receiving. Knowing which treatment they received could affect the results, because what people expect from a treatment can change how they feel or the symptoms they report.'\n    *   **Consider:** 'We have little confidence in the evidence for a few reasons. First, in some studies, people may have known which treatment they were receiving. This could affect the results, as people's expectations can influence how they feel. Also, the studies included different types of people, and we did not find enough studies to be certain about the findings.'",
      "pls_evaluation_summary": "The PLS evaluation shows the draft is highly readable in terms of sentence structure, with 78% of features falling in the best quartile for readability (e.g., Flesch-Kincaid Grade Level is 9.3). However, it deviates significantly from typical PLS patterns in vocabulary complexity. The counts for nouns, complex words (Dale-Chall), 3+ syllable words, and long words are all in the P90 range, indicating the vocabulary is more technical and dense than is typical for a PLS, which could hinder reader comprehension."
    }
  ]
}